<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg"/></p>
<p>该疫苗是一种单剂量预填充产品，用于对 12 岁及以上个体进行基孔肯雅病毒的免疫接种。图片来源：Kitsawet Saethao / Shutterstock.com。</p>
<p>巴伐利亚诺迪克与印度血清研究所（SII）签署了一项制造协议，通过该合同扩大其战略合作伙伴关系，涉及其基孔肯雅疫苗（CHIKV VLP）。</p>
<p>该合同涵盖了从巴伐利亚诺迪克到 SII 的疫苗制造工艺的全面技术转让，旨在提高生产能力并为地方性低收入和中等收入国家的未来供应提供保障。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - 埃博拉 [安卡拉巴伐利亚诺迪克菌株] (多价...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - (恶性疟原虫 + 乙型肝炎) 疫苗</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>这一新安排建立在两家公司现有的 mpox 疫苗许可和制造合作伙伴关系的基础上。</p>
<p>它取代了与生物 E 的早期协议。双方还将探索作为这一扩展合作的一部分的潜在共同开发机会。</p>
<p>巴伐利亚诺迪克的总裁兼首席执行官保罗·查普林表示：“我们很高兴能够加强与印度血清研究所的战略合作伙伴关系。</p>
<p>“通过利用两家组织的优势，我们可以扩大基孔肯雅疫苗的生产，以增加全球供应并改善全球人群的获取。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>CHIKV VLP 疫苗是一种预填充的单剂量、加佐剂的类病毒颗粒重组蛋白产品，旨在对 12 岁及以上人群进行针对基孔肯雅病毒引起的疾病的主动免疫接种。</p>
<p>它旨在触发强烈的血清反应，保护性免疫将在接种后的一周内开始发展。</p>
<p>由于不含病毒遗传物质，该疫苗是非传染性的，无法引起疾病，适合广泛的人群。</p>
<p>以 Vimkunya 为名，CHIKV VLP 于 2025 年获得英国药品和保健产品监管局（MHRA）、欧洲委员会和美国食品药品监督管理局（FDA）的批准。</p>
<p>目前在加拿大和瑞士进行监管审查。</p>
<p>2025 年 9 月，巴伐利亚诺迪克在英国推出了其基孔肯雅疫苗 Vimkunya。</p>
<p>此次推出是在全国报告的与旅行相关的疾病病例显著增加之后进行的。英国健康安全局（UKHSA）表示，与 2024 年同期相比，2025 年 8 月的病例增加了 170%。</p>

医药突破 ETF - ALPS

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

BVNRY

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

<p>巴伐利亚诺迪克公司与印度血清研究所（SII）签署了一项协议，进行基孔肯雅病毒疫苗生产技术转让，以增强低收入和中等收入国家的生产能力。该合作建立在他们现有的 mpox 疫苗合作基础上，并取代了与生物 E 公司的先前协议。CHIKV VLP 疫苗以 Vimkunya 为品牌，在英国、欧盟和美国获得了监管机构的批准，目前正在加拿大和瑞士进行审查。该疫苗旨在改善全球获取，并因英国疾病病例的增加而显示出显著的需求增长</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-2-12-03-2026-shutterstock_2344796289-430x241.jpg"/></p>
<p>The vaccine is a single-dose, prefilled product for immunisation against the chikungunya virus in individuals aged 12 and above. Credit: Kitsawet Saethao / Shutterstock.com.</p>
<div class="lb-trans"><p>该疫苗是一种单剂量预填充产品，用于对 12 岁及以上个体进行基孔肯雅病毒的免疫接种。图片来源：Kitsawet Saethao / Shutterstock.com。</p>
</div><p>Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP).</p>
<div class="lb-trans"><p>巴伐利亚诺迪克与印度血清研究所（SII）签署了一项制造协议，通过该合同扩大其战略合作伙伴关系，涉及其基孔肯雅疫苗（CHIKV VLP）。</p>
</div><p>The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries.</p>
<div class="lb-trans"><p>该合同涵盖了从巴伐利亚诺迪克到 SII 的疫苗制造工艺的全面技术转让，旨在提高生产能力并为地方性低收入和中等收入国家的未来供应提供保障。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Ebola [Ankara Bavarian Nordic Strain] (Multiva...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 埃博拉 [安卡拉巴伐利亚诺迪克菌株] (多价...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - (plasmodium falciparum + hepatitis B) vaccine</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - (恶性疟原虫 + 乙型肝炎) 疫苗</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The new arrangement builds upon the existing licence and manufacturing partnership between the two companies for the mpox vaccine.</p>
<div class="lb-trans"><p>这一新安排建立在两家公司现有的 mpox 疫苗许可和制造合作伙伴关系的基础上。</p>
</div><p>It replaces an earlier deal with Biological E. Both parties will also explore potential co-development opportunities as part of this extended collaboration.</p>
<div class="lb-trans"><p>它取代了与生物 E 的早期协议。双方还将探索作为这一扩展合作的一部分的潜在共同开发机会。</p>
</div><p>Bavarian Nordic’s president and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India.</p>
<div class="lb-trans"><p>巴伐利亚诺迪克的总裁兼首席执行官保罗·查普林表示：“我们很高兴能够加强与印度血清研究所的战略合作伙伴关系。</p>
</div><p>“By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe.”</p>
<div class="lb-trans"><p>“通过利用两家组织的优势，我们可以扩大基孔肯雅疫苗的生产，以增加全球供应并改善全球人群的获取。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunisation against disease caused by the chikungunya virus in people aged 12 years and above.</p>
<div class="lb-trans"><p>CHIKV VLP 疫苗是一种预填充的单剂量、加佐剂的类病毒颗粒重组蛋白产品，旨在对 12 岁及以上人群进行针对基孔肯雅病毒引起的疾病的主动免疫接种。</p>
</div><p>It is designed to trigger a strong seroresponse, with protective immunity beginning to develop as soon as one week following vaccination.</p>
<div class="lb-trans"><p>它旨在触发强烈的血清反应，保护性免疫将在接种后的一周内开始发展。</p>
</div><p>As it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad population demographic.</p>
<div class="lb-trans"><p>由于不含病毒遗传物质，该疫苗是非传染性的，无法引起疾病，适合广泛的人群。</p>
</div><p>Marketed as Vimkunya, CHIKV VLP has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) in 2025.</p>
<div class="lb-trans"><p>以 Vimkunya 为名，CHIKV VLP 于 2025 年获得英国药品和保健产品监管局（MHRA）、欧洲委员会和美国食品药品监督管理局（FDA）的批准。</p>
</div><p>Regulatory review is underway in Canada and Switzerland.</p>
<div class="lb-trans"><p>目前在加拿大和瑞士进行监管审查。</p>
</div><p>In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK.</p>
<div class="lb-trans"><p>2025 年 9 月，巴伐利亚诺迪克在英国推出了其基孔肯雅疫苗 Vimkunya。</p>
</div><p>The launch followed a significant increase in travel-related disease cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences rose by 170% in August 2025 compared with the same period in 2024.</p>
<div class="lb-trans"><p>此次推出是在全国报告的与旅行相关的疾病病例显著增加之后进行的。英国健康安全局（UKHSA）表示，与 2024 年同期相比，2025 年 8 月的病例增加了 170%。</p>
</div>

Bavarian Nordic 与 SII 签署协议以生产基孔肯雅疫苗